MEPERGAN
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 22h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEPERGAN is an injectable combination product approved in 1961 by Hikma, currently in late-stage lifecycle. The generic composition and mechanism of action are not publicly disclosed in available data. This is a legacy injectable medication with established clinical use.
LOE Approaching
Loss of exclusivity is imminent, signaling transition from brand defense to lifecycle management with reduced commercial team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MEPERGAN offers limited career growth due to zero linked job openings and approaching LOE. Roles available focus on operational continuity, cost management, and generic transition planning rather than commercial or innovation initiatives.
Supply Chain ManagerManufacturing Operations
Worked on MEPERGAN at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.